Proteomics takes diabetes marker to America

Perth biotechnology group Proteomics International Laboratories has reached an agreement to exclusively licence its PromarkerD test for diabetes to Sonic Healthcare USA.

An estimated 32 million people or 11 percent of the American population live with diabetes, with PromarkerD the only test available that is able to identify their risk of developing diabetic kidney disease.

Diabetic kidney disease is a major complication arising from diabetes.

Proteomics also manufactures test kits for PromarkerD, the first in the diabetic field that can predict the onset of disease within four years.

The agreement between the two companies will see Proteomics optimise the test for a high-throughput environment within Sonic laboratories, in preparation for a submission to secure a reimbursement code for the test.

The two companies hope to finalise their agreement by 31 December.

Proteomics managing director Dr Richard Lipscombe said the US was the world’s premier market in the diabetes field.

“It is rewarding for us to see their appreciation for what PromarkerD can offer diabetes patients.”

Picture: Proteomics International

Subscribe to our free @AuManufacturing newsletter here.

Share this Story

Stay Informed

Go to Top